Skip to main navigation menu Skip to main content Skip to site footer

Narrative Review

Vol. 10 No. 2 (2007)

β-Adrenergic receptor signaling in cardiac function and heart failure

  • Aasakiran Madamanchi
November 1, 2020




  1. Heart and stroke statistical update. Dallas, Tx: American Heart Association; 2001.
  2. Leimbach WN, Wallin G, Victor RG, et al. Direct evidence from intraneural recordings for increased central sympathetic outflow in patients with heart failure. Circulation 1986; 93: 720-729.
  3. Koch WJ.Genetic and phenotypic targeting of beta-adrenergic signaling in heart failure. Molecular and Cellular Biochemistry 2004; 263: 5-9.
  4. Vassilatis DK, Hohmann JG ,Zeng H, et al. The G proteincoupled receptor repertoires of human and mouse. Proc Natl
  5. Acad Sci U S A 2003; 100: 4903-8.
  6. WessJ. G-protein-coupled receptors:molecular mechanisms involved in receptor activation and selectivity of G-protein
  7. recognition. FASEB J 1997; 11:346-354.
  8. Xiao RP. Beta-adrenergic signaling in the heart: dual coupling of the beta2-adrenergic receptor to G(s) and G(i) proteins. Sci STKE 2001:RE15.
  9. Hoffman BB, Lefkowitz RJ. Catecholamines, sympathetic drugs, and adrenergic receptor anatagonists. In: Hardman J,
  10. Limbird L, editors. The pharmacological basis of therapeutics. 9th ed. New York: McGraw-Hill; 1996:199-248.
  11. Freedman NJ, Lefkowitz RJ.Anti-beta(1)-adrenergic receptor antibodies and heart failure: causation, not just correlation. J
  12. Clin Invest 2004; 113: 1379-82.
  13. Pavoine C, Defer N. The cardiac beta2-adrenergic: signaling a new role for the cPLA2. Cell Signal 2005: 17:141-152.
  14. Ferguson SS. Evolving concepts in G protein-coupled receptor endocytosis: the role in receptor desensitization and signaling. Pharmacology Rev 2001; 53:1-24.
  15. Barak LS, Arabic K, Fang X, et al. Real-time visualization of the cellular redistribution of G protein-coupled receptor kinase 2 and beta-arrestin 2 during homologous desensitization of the substance P receptor. .J Biol Chem 1999; 274:7565-7569.
  16. Freedman NJ, Leggett SB, Drachmann DE, et al. Phosphorylation anddesensitization of the human beta 1-
  17. adrenergic receptor. Involvement of G protein-coupled receptor kinases and cAMP-dependent protein kinase. J Biol Chem 1995: 270:17953-17961.
  18. Perry SJ, Lefkowitz RJ. Arresting developments in heptahelical receptor signaling and regulation. Trends Cell Biol 2002;
  19. :130-8.
  20. Claing A, Laporte SA, Caron MG, et al. Endocytosis of G protein-coupled receptors: roles of G protein-coupled receptor
  21. kinases and beta-arrestin proteins. Prog Neurobiol 202; 66:61-79.
  22. Zhang J, Ferguson SS, Barak LS, et al. Dynamin and betaarrestin reveal distinct mechanisms for G protein-coupled
  23. receptor internalization. J Biol Chem 1996; 271:18302-5.
  24. Esler M, Kaye D, Lambert G, et al. Adrenergic nervous system in heart failure. Am J Cardiol 1997; 80:7L-14L.
  25. Katz AM. Evolving concepts of heart failure: cooling furnace, malfunctioning pump, enlarging muscle. Part II: Hypertrophy and dilatation of the failing heart. J Card Fail 1998; 4:67-81.
  26. Esposito G, Rapacciuolo A, Naga Prasad SV, et al. Genetic alterations that inhibit in vivo pressure-overload hypertrophy
  27. prevent cardiac dysfunction despite increased wall stress. Circulation 2002; 105: 85-92.
  28. Rohrer DK, Desai KH, Jasper JR ,et al. Targeted disruption of the mouse beta1-adrenergic receptor gene:developmental and cardiovascular effects. Proc Natl Acad Sci U S A 1996; 93:7375-80.
  29. Engelhardt S, Hein L,Wiesmann F, et al. Progressive hypertrophy and heart failure in beta1-adrenergic receptor
  30. transgenic mice. Proc Natl Acad Sci U S A1996; 96: 7059-64.
  31. Chruscinski AJ, Rohrer DK, Schauble E, et al. Targeted disruption of the beta2 adrenergic receptor gene. J Biol Chem.
  32. ; 274:16694-16700.
  33. Milano CA, Allen LF, Rockman HA, et al. Enhanced myocardial function in transgenic mice overexpressing the beta 2-
  34. adrenergic receptor. Science 1994; 264: 582-6.
  35. Akhter SA, Skaer CA, Kypson AP, et al. Restoration of betaadrenergic signaling in failing cardiac ventricular myocytes via
  36. adenoviral-mediated gene transfer. Proc Natl Acad Sci U S A 1997; 94:12100-5.
  37. Dorn GW 2nd, Tepe NM, Lorenz JN, et al. Low-and high-level transgenic expression of beta2-adrenergic receptors
  38. differentially affect cardiac hypertrophy and function in Galphaq-overexpressing mice. Proc Natl Acad Sci U S A1999;
  39. : 6400-5.
  40. Freeman K, Lerman I, Kranias EG, et al. Alterations in cardiac adrenergic signaling and calcium cycling differentially affect the progression of cardiomyopathy. J Clin Invest 2001; 107: 967-74.
  41. Du XJ, Autelitano DJ, Dilley RJ, et al. Beta(2)-adrenergic receptor overexpression exacerbates development of heart
  42. failure after aortic stenosis.Circulation 2000; 101:71-77.
  43. Koch WJ, Inglese J, Stone WC, et al. The binding site for the beta gamma subunits of heterotrimeric G proteins on the betaadrenergic receptor kinase. J Biol Chem 1993; 268:8256-60.
  44. Koch WJ, Rockman HA, Samama P, et al. Cardiac function in mice overexpressing the beta-adrenergic receptor kinase or a beta ARK inhibitor. Science 1995; 268:1350-3.
  45. Jaber M, Koch WJ, Rockman H, et al. Essential role of betaadrenergic receptor kinase 1 in cardiac development and
  46. function. Proc Natl Acad Sci U S A 1996; 93:12974-9.
  47. Rockman HA, Choi DJ, Akhter SA, et al. Control of myocardial contractile function by the level of beta-adrenergic receptor kinase 1 in gene-targeted mice. .J Biol Chem 1998; 273:18180-4.
  48. Bristow MR. Why does the myocardium fail? Insights from basic science. Lancet 1998; 352 Suppl 1:SI8-14.
  49. Shah AS, White DC, Emani S, et al. In vivo ventricular gene delivery of a beta-adrenergic receptor kinase inhibitor to the
  50. failing heart reverses cardiac dysfunction. Circulation 2001; 103: 1311-6.
  51. Eckhart AD, Duncan SJ, Penn RB, et al. Hybrid transgenic mice reveal in vivo specificity of G protein-coupled receptor kinases in the heart. Circ Res 2000; 86:43-50.
  52. Li Z, Laugwitz KL, Pinkernell K, et al. Effects of two Gbetagamma-binding proteins—N-terminally truncated
  53. phosducin and beta-adrenergic receptor kinase C terminus (betaARKct)—in heart failure. Gene Ther 2003; 10: 1354-61.
  54. Rameh LE, Cantley LC. The role of phosphoinositide 3-kinase lipid products in cell function. J Biol Chem 1999; 274:8347-50.
  55. Shioi T, Kang PM, Douglas PS, et al. The conserved phosphoinositide 3-kinase pathway determines heart size in
  56. mice. EMBO J 2000; 19:2537-48.
  57. Crackower MA, Oudit GY, Kozieradzki I,et al. Regulation of myocardial contractility and cell size by distinct PI3K-PTEN
  58. signaling pathways. Cell 2002; 110:737-749.
  59. Naga Prasad SV, Laporte SA, Chamberlain D, et al. Phosphoinositide 3-kinase regulates beta2-adrenergic receptor
  60. endocytosis by AP-2 recruitment to the receptor/beta-arrestin complex. J Cell Biol 2002; 158:563-575.
  61. Naga Prasad SV, Jayatilleke A, Madamanchi A, et al. Protein kinase activity of phosphoinositide 3-kinase regulates betaadrenergic receptor endocytosis. Nat Cell Biol 2005; 7:785-796.
  62. Perrino C, Naga Prasad SV, Patel M, et al. Targeted inhibition of beta-adrenergic receptor kinase-1-associated phosphoinositide-3 kinase activity preserves beta-adrenergic receptor signaling and prolongs survival in heart failure induced by calsequestrin overexpression. J Am Coll Cardiol 2005; 45:1862-70.


Download data is not yet available.